Article and Video CATEGORIES
Blood Cancers OncTalk 2024
The Blood Cancers OncTalk was a live, virtual, interactive patient education event hosted in October 2024 that included presentations and panel discussions covering general subjects relevant to a diverse range of blood cancers and treatment options and an opportunity to speak with the experts in a Q&A session.
Image
This event was moderated by Dr. Sridevi Rajeeve, Memorial Sloan Kettering, joined by speakers: Dr. Hamza Hashmi, Memorial Sloan Kettering, Dr. Michele Stanchina, University of Miami, Dr. Muhammad Salman Faisal, Oklahoma University, and Dr. Andrew Srisuwananukorn, Ohio State University
Topics include:
- Myeloma 101: Facts and Fiction of the 'Myeloma Marathon'
- Updates in DLBCL
- Treatment Basics of Bone Marrow Transplant
- Frontline Therapies in Myelofibrosis
- Panel Discussions and a Question-and-Answer session
To watch the complete playlist, click here.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.